Antimicrobial Drugs: Mechanisms, Clinical Use, and Resistance

Antimicrobial Drugs: Mechanisms, Clinical Use, and Resistance

Introduction to Antimicrobial Agents

Antimicrobial drugs are essential tools in controlling microbial growth within the body. They are classified based on their origin, structure, and mechanism of action. Understanding their history, mechanisms, and clinical considerations is crucial for effective and safe use in medicine.

• Drugs: Chemicals that affect physiology in any manner.

• Chemotherapeutic agents: Drugs that act against diseases.

• Antimicrobial agents (antimicrobials): Drugs that treat infections caused by microorganisms.

History and Sources of Antimicrobial Agents

The development of antimicrobial drugs has revolutionized medicine. Key historical figures and discoveries include:

• Paul Ehrlich: Developed "magic bullets" (arsenic compounds) targeting microbes.

• Alexander Fleming: Discovered penicillin from Penicillium mold.

• Gerhard Domagk: Discovered sulfanilamide, the first widely used antimicrobial.

• Selman Waksman: Coined the term "antibiotics" for naturally produced antimicrobial agents.

Antimicrobials can be:

• Natural: Produced by microorganisms (e.g., penicillin from fungi).

• Semisynthetic: Chemically modified natural antibiotics for improved efficacy.

• Synthetic: Completely synthesized in the laboratory.

Mechanisms of Antimicrobial Action

Antimicrobial drugs target specific structures or functions in microbes, aiming for selective toxicity—harming the pathogen without damaging the host.

Inhibition of Cell Wall Synthesis

• Beta-lactams (e.g., penicillins, cephalosporins): Prevent cross-linkage of peptidoglycan in bacterial cell walls, leading to cell lysis.

• Vancomycin and cycloserine: Interfere with bridges linking NAM subunits in Gram-positive bacteria.

• Bacitracin: Blocks transport of peptidoglycan precursors.

• Isoniazid and ethambutol: Disrupt mycolic acid synthesis in mycobacteria.

• Echinocandins: Inhibit fungal cell wall synthesis by blocking glucan formation.

Note: These drugs are effective only on actively growing cells and do not affect existing peptidoglycan.

Inhibition of Protein Synthesis

• Target prokaryotic ribosomes (70S), which differ from eukaryotic ribosomes (80S), allowing selective inhibition.

• Some drugs (e.g., mupirocin) interfere with tRNA charging, specifically inhibiting certain aminoacyl-tRNA synthetases.

• Caution: Mitochondria in eukaryotes have 70S ribosomes, so some drugs may have side effects.

Disruption of Cytoplasmic Membranes

• Drugs like nystatin and amphotericin B bind to ergosterol in fungal membranes, forming pores and causing cell death.

• Polymyxin: Disrupts Gram-negative bacterial membranes but is toxic to human kidneys.

• Azoles and allylamines inhibit ergosterol synthesis in fungi.

Inhibition of Metabolic Pathways

• Antimetabolites block unique microbial metabolic processes (e.g., sulfonamides inhibit folic acid synthesis).

• Some drugs interfere with protozoan and viral metabolism (e.g., atovaquone, amantadine).

• Protease inhibitors block viral replication enzymes (notably in HIV).

Inhibition of Nucleic Acid Synthesis

• Quinolones and fluoroquinolones inhibit DNA gyrase in bacteria.

• Nucleotide/nucleoside analogs disrupt DNA/RNA synthesis, often used against viruses and cancer cells.

• Reverse transcriptase inhibitors target HIV-specific enzymes.

Prevention of Virus Attachment, Entry, or Uncoating

• Attachment antagonists block viral binding to host cells (e.g., pleconaril).

• Uncoating inhibitors prevent viral genome release (e.g., arildone).

Clinical Considerations in Prescribing Antimicrobial Drugs

Ideal Properties of Antimicrobial Agents

• Readily available, inexpensive, chemically stable, easily administered, nontoxic, nonallergenic, and selectively toxic.

Spectrum of Action

• Narrow-spectrum: Effective against a limited range of pathogens.

• Broad-spectrum: Effective against a wide variety of organisms, but may disrupt normal flora and cause superinfections.

Testing Antimicrobial Effectiveness

• Diffusion susceptibility (Kirby-Bauer) test: Measures zones of inhibition around antibiotic disks on an agar plate.

• Minimum inhibitory concentration (MIC) test: Determines the lowest concentration of drug that inhibits visible growth.

• Minimum bactericidal concentration (MBC) test: Identifies the lowest concentration that kills the organism.

Routes of Administration

• Topical: For external infections.

• Oral: Convenient, self-administered, but absorption may be variable.

• Intramuscular (IM): Injection into muscle for moderate absorption.

• Intravenous (IV): Directly into bloodstream for rapid, high levels.

Safety and Side Effects

• Toxicity: Some drugs may harm kidneys, liver, or nerves; therapeutic index (TI) is the ratio of tolerated dose to effective dose.

• Allergies: Rare but can be severe (e.g., anaphylactic shock).

• Disruption of normal microbiota: May lead to secondary infections or overgrowth of opportunistic organisms.

Resistance to Antimicrobial Drugs

Development of Resistance

Microbial resistance arises through genetic mutations or acquisition of resistance genes (R plasmids) via transformation, transduction, or conjugation. Some pathogens are naturally resistant, while others acquire resistance over time.

Mechanisms of Resistance

• Enzyme production that destroys or deactivates the drug (e.g., beta-lactamase).

• Prevention of drug entry into the cell.

• Alteration of drug targets to reduce binding.

• Changes in metabolic pathways.

• Efflux pumps that expel the drug.

• Biofilm formation for protection.

• Special proteins (e.g., MfpA in Mycobacterium tuberculosis) that protect target enzymes.

Multiple Resistance and Cross Resistance

• Pathogens may become resistant to multiple drugs, especially in healthcare settings.

• Cross resistance occurs when drugs share similar structures or mechanisms.

Retarding Resistance

• Maintain high drug concentrations to ensure pathogen elimination.

• Use drug combinations (synergism enhances effect; antagonism reduces efficacy).

• Limit antimicrobial use to necessary cases.

• Develop new drugs and modify existing ones to overcome resistance.

Summary Table: Common Antibiotics and Their Sources

Source	Microorganism	Antimicrobial
Fungi	Penicillium chrysogenum	Penicillin G
Fungi	Penicillium griseofulvum	Griseofulvin
Bacteria	Streptomyces griseus	Streptomycin
Bacteria	Bacillus polymyxa	Polymyxin
Bacteria	Saccharopolyspora erythraea	Erythromycin
Bacteria	Streptomyces aureofaciens	Tetracycline
Bacteria	Streptomyces venezuelae	Chloramphenicol
Bacteria	Streptomyces nodosus	Amphotericin B
Bacteria	Streptomyces noursei	Nystatin

Key Equations

• Therapeutic Index (TI):

$\text{Therapeutic\ Index\ (TI)} = \frac{\text{Toxic\ Dose\ for\ 50\%\ of\ population}}{\text{Effective\ Dose\ for\ 50\%\ of\ population}}$

Conclusion

Antimicrobial drugs are vital in treating infectious diseases, but their effectiveness is threatened by the development of resistance. Understanding their mechanisms, clinical use, and strategies to prevent resistance is essential for future healthcare professionals.